These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 37434391)

  • 1. Brigatinib in Japanese patients with ALK-positive non-small-cell lung cancer: Final results of the phase 2 J-ALTA trial.
    Yoshida T; Kumagai T; Toyozawa R; Katayama R; Nishio M; Seto T; Goto K; Yamamoto N; Ohe Y; Kudou K; Asato T; Zhang P; Nakagawa K
    Cancer Sci; 2023 Sep; 114(9):3698-3707. PubMed ID: 37434391
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Brigatinib in Japanese patients with tyrosine kinase inhibitor-naive ALK-positive non-small cell lung cancer: first results from the phase 2 J-ALTA study.
    Sugawara S; Kondo M; Yokoyama T; Kumagai T; Nishio M; Goto K; Nakagawa K; Seto T; Yamamoto N; Kudou K; Asato T; Zhang P; Ohe Y
    Int J Clin Oncol; 2022 Dec; 27(12):1828-1838. PubMed ID: 36036294
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Brigatinib in Japanese Patients With ALK-Positive NSCLC Previously Treated With Alectinib and Other Tyrosine Kinase Inhibitors: Outcomes of the Phase 2 J-ALTA Trial.
    Nishio M; Yoshida T; Kumagai T; Hida T; Toyozawa R; Shimokawaji T; Goto K; Nakagawa K; Ohe Y; Seto T; Kudou K; Asato T; Zhang P; Yamamoto N
    J Thorac Oncol; 2021 Mar; 16(3):452-463. PubMed ID: 33248320
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of Brigatinib in Patients With Advanced ALK-Positive NSCLC Who Progressed on Alectinib or Ceritinib: ALK in Lung Cancer Trial of brigAtinib-2 (ALTA-2).
    Ou SI; Nishio M; Ahn MJ; Mok T; Barlesi F; Zhou C; Felip E; de Marinis F; Kim SW; Pérol M; Liu G; Migliorino MR; Kim DW; Novello S; Bearz A; Garrido P; Mazieres J; Morabito A; Lin HM; Yang H; Niu H; Zhang P; Kim ES
    J Thorac Oncol; 2022 Dec; 17(12):1404-1414. PubMed ID: 36096442
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Brigatinib Versus Alectinib in ALK-Positive NSCLC After Disease Progression on Crizotinib: Results of Phase 3 ALTA-3 Trial.
    Yang JC; Liu G; Lu S; He J; Burotto M; Ahn MJ; Kim DW; Liu X; Zhao Y; Vincent S; Yin J; Ma X; Lin HM; Popat S
    J Thorac Oncol; 2023 Dec; 18(12):1743-1755. PubMed ID: 37574132
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Brigatinib Versus Crizotinib in ALK Inhibitor-Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial.
    Camidge DR; Kim HR; Ahn MJ; Yang JCH; Han JY; Hochmair MJ; Lee KH; Delmonte A; Garcia Campelo MR; Kim DW; Griesinger F; Felip E; Califano R; Spira AI; Gettinger SN; Tiseo M; Lin HM; Liu Y; Vranceanu F; Niu H; Zhang P; Popat S
    J Thorac Oncol; 2021 Dec; 16(12):2091-2108. PubMed ID: 34537440
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial.
    Gettinger SN; Bazhenova LA; Langer CJ; Salgia R; Gold KA; Rosell R; Shaw AT; Weiss GJ; Tugnait M; Narasimhan NI; Dorer DJ; Kerstein D; Rivera VM; Clackson T; Haluska FG; Camidge DR
    Lancet Oncol; 2016 Dec; 17(12):1683-1696. PubMed ID: 27836716
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Iruplinalkib (WX-0593) Versus Crizotinib in ALK TKI-Naive Locally Advanced or Metastatic ALK-Positive NSCLC: Interim Analysis of a Randomized, Open-Label, Phase 3 Study (INSPIRE).
    Shi Y; Chen J; Yang R; Wu H; Wang Z; Yang W; Cui J; Zhang Y; Liu C; Cheng Y; Liu Y; Shan J; Wang D; Yang L; Hu C; Zhao J; Cao R; Tan B; Xu K; Si M; Li H; Mao R; Li L; Kang X; Wang L
    J Thorac Oncol; 2024 Jun; 19(6):912-927. PubMed ID: 38280448
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ALTA-2: Phase II study of brigatinib in patients with ALK-positive, advanced non-small-cell lung cancer who progressed on alectinib or ceritinib.
    Kim ES; Barlesi F; Mok T; Ahn MJ; Shen J; Zhang P; Ou SI
    Future Oncol; 2021 May; 17(14):1709-1719. PubMed ID: 33569983
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and Safety of Brigatinib Compared With Crizotinib in Asian vs. Non-Asian Patients With Locally Advanced or Metastatic ALK-Inhibitor-Naive ALK+ Non-Small Cell Lung Cancer: Final Results From the Phase III ALTA-1L Study.
    Ahn MJ; Kim HR; Yang JCH; Han JY; Li JY; Hochmair MJ; Chang GC; Delmonte A; Lee KH; Campelo RG; Gridelli C; Spira AI; Califano R; Griesinger F; Ghosh S; Felip E; Kim DW; Liu Y; Zhang P; Popat S; Camidge DR
    Clin Lung Cancer; 2022 Dec; 23(8):720-730. PubMed ID: 36038416
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Indirect comparisons of brigatinib and alectinib for front-line
    Reckamp KL; Lin HM; Cranmer H; Wu Y; Zhang P; Walton LJ; Kay S; Cichewicz A; Neupane B; Fahrbach K; Popat S; Camidge DR
    Future Oncol; 2022 Jun; 18(20):2499-2510. PubMed ID: 35608148
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Brigatinib Versus Crizotinib in Advanced ALK Inhibitor-Naive ALK-Positive Non-Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial.
    Camidge DR; Kim HR; Ahn MJ; Yang JCH; Han JY; Hochmair MJ; Lee KH; Delmonte A; García Campelo MR; Kim DW; Griesinger F; Felip E; Califano R; Spira A; Gettinger SN; Tiseo M; Lin HM; Gupta N; Hanley MJ; Ni Q; Zhang P; Popat S
    J Clin Oncol; 2020 Nov; 38(31):3592-3603. PubMed ID: 32780660
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Brigatinib in Crizotinib-Refractory ALK+ NSCLC: 2-Year Follow-up on Systemic and Intracranial Outcomes in the Phase 2 ALTA Trial.
    Huber RM; Hansen KH; Paz-Ares Rodríguez L; West HL; Reckamp KL; Leighl NB; Tiseo M; Smit EF; Kim DW; Gettinger SN; Hochmair MJ; Kim SW; Langer CJ; Ahn MJ; Kim ES; Kerstein D; Groen HJM; Camidge DR
    J Thorac Oncol; 2020 Mar; 15(3):404-415. PubMed ID: 31756496
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-Term Efficacy and Safety of Brigatinib in Crizotinib-Refractory
    Gettinger SN; Huber RM; Kim DW; Bazhenova L; Hansen KH; Tiseo M; Langer CJ; Paz-Ares Rodríguez LG; West HL; Reckamp KL; Weiss GJ; Smit EF; Hochmair MJ; Kim SW; Ahn MJ; Kim ES; Groen HJM; Pye J; Liu Y; Zhang P; Vranceanu F; Camidge DR
    JTO Clin Res Rep; 2022 Sep; 3(9):100385. PubMed ID: 36065449
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Brigatinib vs alectinib in crizotinib-resistant advanced anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALTA-3).
    Popat S; Liu G; Lu S; Song G; Ma X; Yang JC
    Future Oncol; 2021 Nov; 17(32):4237-4247. PubMed ID: 34423676
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Brigatinib in patients with ALK-positive advanced non-small-cell lung cancer pretreated with sequential ALK inhibitors: A multicentric real-world study (BRIGALK study).
    Descourt R; Perol M; Rousseau-Bussac G; Planchard D; Mennecier B; Wislez M; Cortot A; Guisier F; Galland L; Dô P; Schott R; Dansin E; Arrondeau J; Auliac JB; Chouaid C
    Lung Cancer; 2019 Oct; 136():109-114. PubMed ID: 31491676
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exploratory Analysis of Brigatinib Activity in Patients With Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer and Brain Metastases in Two Clinical Trials.
    Camidge DR; Kim DW; Tiseo M; Langer CJ; Ahn MJ; Shaw AT; Huber RM; Hochmair MJ; Lee DH; Bazhenova LA; Gold KA; Ou SI; West HL; Reichmann W; Haney J; Clackson T; Kerstein D; Gettinger SN
    J Clin Oncol; 2018 Sep; 36(26):2693-2701. PubMed ID: 29768119
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-Positive Advanced Non-Small Cell Lung Cancer in the Global Phase III ALEX Study.
    Camidge DR; Dziadziuszko R; Peters S; Mok T; Noe J; Nowicka M; Gadgeel SM; Cheema P; Pavlakis N; de Marinis F; Cho BC; Zhang L; Moro-Sibilot D; Liu T; Bordogna W; Balas B; Müller B; Shaw AT
    J Thorac Oncol; 2019 Jul; 14(7):1233-1243. PubMed ID: 30902613
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer.
    Camidge DR; Kim HR; Ahn MJ; Yang JC; Han JY; Lee JS; Hochmair MJ; Li JY; Chang GC; Lee KH; Gridelli C; Delmonte A; Garcia Campelo R; Kim DW; Bearz A; Griesinger F; Morabito A; Felip E; Califano R; Ghosh S; Spira A; Gettinger SN; Tiseo M; Gupta N; Haney J; Kerstein D; Popat S
    N Engl J Med; 2018 Nov; 379(21):2027-2039. PubMed ID: 30280657
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-world treatment outcomes with brigatinib in patients with pretreated ALK+ metastatic non-small cell lung cancer.
    Popat S; Brustugun OT; Cadranel J; Felip E; Garassino MC; Griesinger F; Helland Å; Hochmair M; Pérol M; Bent-Ennakhil N; Kruhl C; Novello S
    Lung Cancer; 2021 Jul; 157():9-16. PubMed ID: 34051652
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.